Q2 2026 13F · SEC CIK 1512848

NEA Management Company, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $1.6B
Reported positions: 26
Top holdings a year, 3 yrs: +36.2%
Assets under management: $35.6B

NEA Management Company, LLC is a hedge fund that reported 26 positions worth $1.6B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Trevi Therapeutics Inc (TRVI, 15.5%), Mbx Biosciences Inc (MBX, 12.6%), Monte Rosa Therapeutics Inc (GLUE, 11.7%). A portfolio copying its top holdings returned 36.2% a year over the last 3 years, against 22.3% for the S&P 500.

NEA Management Company, LLC holdings all 26 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

NEA Management Company, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
TRVITrevi Therapeutics Inc	15.5%	9.0%	13,222,228	+0.0%	$246.6M
MBXMbx Biosciences Inc	12.6%	6.1%	3,614,486	+0.0%	$199.5M
GLUEMonte Rosa Therapeutics Inc	11.7%	7.2%	7,692,298	+0.0%	$186.2M
CELCCelcuity Inc	11.3%	14.8%	1,710,561	-25.2%	$179.0M
SGPSpyglass Pharma Inc	10.4%	10.9%	7,392,301	+0.0%	$164.6M
SVRASavara Inc	9.5%	7.6%	24,471,264	+0.0%	$150.7M
ZBIOZenas Biopharma Inc	6.4%	4.5%	4,023,219	+0.0%	$102.1M
COURCoursera Inc	4.6%	4.3%	12,867,769	+0.0%	$72.6M
AUPHAurinia Pharmaceuticals Inc	4.2%	3.3%	3,969,834	+0.0%	$67.4M
CRSPCrispr Therapeutics AG	3.6%	2.9%	1,058,570	+0.0%	$57.7M
ORICOric Pharmaceuticals Inc	2.8%	3.0%	4,118,621	+0.0%	$44.6M
PHATPhathom Pharmaceuticals Inc Com	1.3%	1.2%	1,960,169	+0.0%	$21.3M
KRROKorro Bio Inc	1.1%	0.8%	1,297,893	+0.0%	$17.1M
XFORX4 Pharmaceuticals, Inc.	1.0%	0.8%	3,233,743	+0.0%	$15.1M
CSBRChampions Oncology, Inc.	0.7%	0.6%	1,713,720	+0.0%	$10.6M
NKTXNkarta Inc	0.6%	0.4%	3,568,781	+0.0%	$10.1M
CVRXCvrx Inc	0.6%	1.1%	1,954,440	-3.5%	$10.0M
BDTXBlack Diamond Therapeutics, Inc.	0.5%	0.5%	4,448,757	+0.0%	$8.2M
KPTIKaryopharm Therapeutics Inc	0.4%	New	576,780	—	$5.6M
IVAInventiva SA	0.3%	0.5%	1,462,586	+0.0%	$5.5M
LONALeonabio Inc	0.3%	0.3%	464,398	+0.0%	$4.3M
SNTISenti Biosciences, Inc.	0.3%	0.2%	3,775,615	+0.0%	$4.2M
MRKRMarker Therapeutics Inc	0.1%	0.1%	1,625,678	+0.0%	$2.4M
OKUROnkure Therapeutics Inc	0.1%	0.1%	478,548	+0.0%	$2.2M
IMAImagenebio Inc	0.0%	0.0%	50,005	+0.0%	$295K
GOSSGossamer Bio Inc	0.0%	0.0%	1,000,000	+0.0%	$165K

What NEA Management Company, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

KPTI Karyopharm Therapeutics Inc0.4% of 13F

Added to

No position grew by more than 5%.

Reduced

CELC Celcuity Inc-25.2% shares

Sold out

ACLX Arcellx Incwas 19.9%

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: -1.6% /yr; S&P 500 +11.7%
3 years: +36.2% /yr; S&P 500 +22.3%
5 years: -12.4% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$1.6B	26
Q1 2026	$1.8B	26
Q4 2025	$2.0B	27
Q3 2025	$1.8B	29
Q2 2025	$1.3B	32
Q1 2025	$1.3B	37
Q4 2024	$1.8B	41
Q3 2024	$1.8B	42
Q2 2024	$1.3B	41
Q1 2024	$1.6B	44
Q4 2023	$1.5B	44
Q3 2023	$1.3B	46

Questions about NEA Management Company, LLC's portfolio

What stocks does NEA Management Company, LLC own?

NEA Management Company, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 26 positions worth $1.6B. The largest are Trevi Therapeutics Inc (TRVI) at 15.5%, Mbx Biosciences Inc (MBX) at 12.6%, Monte Rosa Therapeutics Inc (GLUE) at 11.7%, Celcuity Inc (CELC) at 11.3% and Spyglass Pharma Inc (SGP) at 10.4%.

What did NEA Management Company, LLC buy last quarter?

In Q2 2026, NEA Management Company, LLC added a new position in Karyopharm Therapeutics Inc (KPTI), compared with its Q1 2026 filing.

What did NEA Management Company, LLC sell last quarter?

In Q2 2026, NEA Management Company, LLC sold all of Arcellx Inc (ACLX) and Celcuity Inc (CELC) (-25.2% shares), compared with its Q1 2026 filing.

How has NEA Management Company, LLC's portfolio performed?

A portfolio copying NEA Management Company, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +36.2% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: -1.6% against +11.7%. Over 5 years: -12.4% a year against +10.6%.

When is NEA Management Company, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. NEA Management Company, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does NEA Management Company, LLC manage?

NEA Management Company, LLC reported $35.6B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.6B.